Rankings
▼
Calendar
REGN Q3 2017 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
REGN
Regeneron Pharmaceuticals, Inc.
$81B
Q3 2017 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$1.5B
+23.0% YoY
Gross Profit
$1.4B
90.5% margin
Operating Income
$560M
37.3% margin
Net Income
$388M
25.9% margin
EPS (Diluted)
$3.32
QoQ Revenue Growth
+2.1%
Cash Flow
Operating Cash Flow
$415M
Free Cash Flow
$355M
Stock-Based Comp.
$125M
Balance Sheet
Total Assets
$8.7B
Total Liabilities
$2.6B
Stockholders' Equity
$6.1B
Cash & Equivalents
$792M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$1.5B
$1.2B
+23.0%
Gross Profit
$1.4B
$1.1B
+18.3%
Operating Income
$560M
$363M
+54.3%
Net Income
$388M
$265M
+46.6%
Revenue Segments
Antibody Collaboration
$162M
66%
Immuno-oncology Agreement
$83M
34%
← FY 2017
All Quarters
Q4 2017 →